Melanoma vaccine based on the vector of membrane fusogenic liposomes

Pharmazie

Volumn 59, Issue 4, 2004, Pages 263-267

  Qiang, Li ^a,b   Yi, Jin ^a   Fu De, Cui ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; LIPOSOME; MELANOMA VACCINE; MEMBRANE FUSOGENIC LIPOSOME; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG ISOLATION; DRUG MANUFACTURE; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INSTRUMENT; MELANOMA; MELANOMA CELL; MEMBRANE FUSION; MOUSE; NONHUMAN; SENDAI VIRUS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN G; LIPOSOMES; MELANOMA, EXPERIMENTAL; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED C57BL; SENDAI VIRUS; VIRAL FUSION PROTEINS;

EID: 1842733345     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ahmann DL, Creagan ET, Hahn RG et al. (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63: 224-227.
2. Amselem S, Loyter A, Lichtenberg D et al. (1985) The interaction of Sendai virus with negatively charged liposomes: virus-induced lysis of carboxyfluorescein-loaded small unilamellar vesicles. Biochim Biophys Acta 820: 1-10.
3. Arkema A, Huckriede A, Schoen P et al. (2000) Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18: 1327-33.
4. Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291-299.
5. Hosaka Y (1988) Sendai virion structure and its interaction with cellular membranes. Electron Microsc Rev 1: 17-38.
6. Hu Y, Jin Y, Wang H (2002) Study on the transfection efficiency of antisense oligodeoxynucleotide against telomerase by cationic fusogenic liposome. Acta Pharm Sin 37: 892-896.
7. Ishida N, Homma M (1978) Sendai virus. Adv Virus Res 23: 349-383.
8. Jondal M, Schirmbeck R, Reimann J (1996) MHC-restricted CTL responses to exogenous antigens. Immunity 5: 295-302.
9. Kato K, Nakanishi M, Kaneda Y et al. (1991) Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. J Biol Chem 266: 3361-3364.
10. Kitajima I, Hanyu N, Soejima Y et al. (1997) Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. J Biol Chem 272: 27099-27106.
11. Kunisawa J, Nakagawa S, Mayumi T (2001) Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Delivery Rev. 52: 177-186.
12. Markwell MA, Paulson JC (1980) Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants. Proc Natl Acad Sci USA 77: 5693-5697.
13. Mizuguchi H, Nakagawa T, Morioka Y et al. (1997) Cytoplasmic gene expression system enhances the efficiency of cationic liposome-mediated in vivo gene transfer into mouse brain. Biochem Biophys Res Commun 234: 15-18.
14. Mizuguchi H, Nakanishi M, Nakanishi T et al. (1996) Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Br J Cancer 73: 472-476.
15. Nakanishi M, Mizuguchi H, Ashihara K et al. (1999) Gene delivery systems using the Sendai virus. Mol Membr Biol 16: 123-127
16. Reis e Sousa C, Germain RN (1995) Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 182: 841-851.
17. Rock KL, Rothstein L, Gamble S et al. (1993) Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 150: 438-446.
18. Schadendorf D, Paschen A, Sun Y (2000) Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol Lett 74: 67-74.
19. Sheikh NA, Al-Shamisi M, Morrow WJ (2000) Delivery systems for molecular vaccination. Curr Opin Mol Ther 2: 37-54.
20. Sun Y, Jurgovky K, Moller P et al. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5: 481-490.